Finally scientific certainty!
protexam Tests
on the management of prostate cancer diagnosis
Prostate cancer is very common. Only a very few forms pose a direct threat. The majority of prostate cancers grow very slowly, are confined to the prostate gland, and require minimal or no treatment.
Active surveillance requires the patient’s trust in the informative value of the diagnostic and, if necessary, therapeutic measures.
Protexam’s prostate diagnostic management is a quantum leap in diagnostics!
Turning point - results of the ProtecT study
Whether treated (surgery/radiation) or not, only about 2.7% of prostate cancer patients die, but 90% were treated, with all the side effects!
Prof. Peter Albers, Director of the Department of Urology at the University Hospital Düsseldorf and Head of the Department at the German Cancer Research Center in Heidelberg, summarizes the results of the ProtecT studies [FAZ article by H. Kaulen, April 5, 2023]:
- The ISUP Grade Group 1 and 2 carcinomas that have been operated on so far can be treated much more conservatively (no therapy). The guideline must be changed. We must educate patients better - this must be paid for!
Only the protexam test eliminates the dilemma:
- It is the only biomarker for prostate cancer, it detects life-threatening prostate cancer with the highest accuracy - 94% (negative predictive value).
This is where the PCU and PSM test from protexam helps:
The PCU (Prostate Check-Up) test detects prostate cancer as a biomarker.
The PSM (Prostate Status Management) test determines the aggressiveness of prostate cancer.
Active monitoring is possible at any time - again and again - using urine (blood filtrate) with the PSM test from protexam!
Why the protexam test?
- only biomarker for prostate cancer and associated with pathophysiologyhighest available accuracy - 94% safe - simple - accurate - from urine (the filtrate of the blood)
All diseases, including cancer, arise at the level of cells, which are controlled by proteins.
By decoding the proteome, the totality of proteins, the degenerated cell that forms the basis of cancer can also be detected early.
Specific changes that lead to cancer - such as prostate cancer - are demonstrated by specific protein patterns that have been demonstrated in evidence-based studies.
According to the latest studies, including the ProtecT study with 84,000 patients over 15 years, neither the digital resection findings (DRE), nor the PSA test or the tissue determination (Gleason 3 4) justify further biopsies or therapeutic measures.
This dilemma can be solved with protexam tests!
DRU and PSA test
The digital rectal examination (DRE) is rejected because of its high inaccuracy.
The PSA test (prostate-specific antigen test) is not a biomarker for prostate cancer and, with only 30% detection and an incorrect statement in 80% of cases, it is more of a presumption. Especially since, according to the ProtecT study, 50% of fatal prostate tumors are not detected. Since the PSA test is not suitable for screening, it is not covered by health insurance companies. In the USA, PSA screening is no longer carried out due to the high level of reimbursement damages and insurance policies. Nevertheless, PSA screening can be very useful with the necessary correction
What is a useful next step after a positive PSA result?
Tissue sample/biopsy
The introduction of punches is an invasive procedure that can only be justified with the reliable identification of aggressive prostate cancer. Until now, even tissue analyses with stages 3 4 (Gleason score 7) carcinomas were treated as significant tumors, which led to surgical removal or radiation.
However, according to the results of the ProtecT study, cases of patients with Gleason score 7 should undergo active observation.
Regular observation through a biopsy, which can repeatedly lead to injuries to the intestine and prostate with bleeding and the risk of sepsis, is therefore out of the question.
Imaging / MRI
Imaging techniques such as ultrasound, MRI or mpMRI (multiparametric magnetic resonance imaging) can determine the size and location of prostate cancer.
All of these procedures are not able to determine whether the tissue change is benign or cancerous, or even to check its aggressiveness.
The mpMRI is unsuitable as a correction or result because it fails to detect up to 80% of tumors and is not without side effects (contrast agent). The mpMRI can only detect massive tissue changes without being able to determine whether it is an aggressive cancer (no pathophysiological association).